On Qilu Huahai, stone medicine ... "grab food" 300 million anti-epileptic drugs.

Pharmaceutical Network July 13th, recently, Huahai Pharmaceuticals can be said to be a happy eventCDE website shows that, following the July 7 huahai Pharmaceuticals' Alyssakou collapse tablet 3 imitation listing application was accepted, July 10, Huahai Pharmaceuticals' Primain capsule 4 imitation listing application was accepted- and china's public medical institutions terminal Pribarin capsule sales of more than 300 million yuan in 2019, currently, only Qilu Pharmaceuticals has been ratedin recent years, China's public medical institutions terminal Pribarin capsule sales (units: 10,000 yuan) minet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal Pribarin capsule sales of more than 300 million yuan, up 48.78 percent year-on-year, manufacturers only Pfizer and Chongqing Saiwei Pharmaceuticals two, of which Pfizer occupies 60 percent of the market sharein February this year, Qilu Pharmaceuticals with four types of imitation declaration of Pribarin capsules approved, and as the same through the consistency evaluation, is also the first evaluation of the product's enterprisesBefore, Pribarin capsules to 4 types of imitation declaration of enterprises have stone pharmaceutical group Oyi Pharmaceutical, Jiangsu Enhua Pharmaceuticals, China Resources Shuanghe Pharmaceutical seventy-sevensource: CDE official website, the net database of the meter, if there is a leak, please point to the positive.